REGENXBIO Inc. filings document governance, operating results and material events for a biotechnology company developing AAV gene therapies. Recent 8-K disclosures include quarterly and annual results, FDA communications involving RGX-121 and RGX-111, and regulatory updates tied to a Biologics License Application and investigational new drug applications.
The filing record also covers collaboration and license matters, including an amendment to the AbbVie collaboration for surabgene lomparvovec and a settlement related to the GSK-REGENXBIO sublicense. Proxy materials describe board elections, stockholder meeting matters, executive compensation, equity awards and other governance disclosures for the Delaware corporation.
REGENXBIO Inc. (RGNX) is asking stockholders to vote at its May 29, 2026 annual meeting on six key items, including electing three Class II directors to serve until 2029 and ratifying PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026.
Stockholders will also cast a non-binding advisory vote on 2025 executive compensation and decide on two stock option exchange programs. One program would let non‑executive employees, and a separate one would let executive employees, voluntarily surrender underwater stock options for a smaller number of replacement options priced at current fair market value.
The proxy highlights REGENXBIO’s clinical progress in gene therapy, including ABBV‑RGX‑314 trials in eye diseases, RGX‑202 in Duchenne muscular dystrophy, and RGX‑121 for MPS II, as well as a $110.0 million upfront payment from a Nippon Shinyaku partnership and a royalty bond agreement of up to $250 million. The company reports ending 2025 with $240.9 million in cash, cash equivalents and marketable securities.
REGENXBIO Inc. is asking shareholders to vote at its May 29, 2026 Annual Meeting on director elections, ratification of PwC as auditor, an advisory "say-on-pay" vote, and two related stock option exchange proposals for non-executive and executive employees. The company highlights 2025 progress: completion of key trial enrollments 1,200 participants in ABBV-RGX-314 pivotal trials), a strategic partnership with Nippon Shinyaku with a $110.0 million upfront payment, and a $150.0 million royalty bond close with up to $250.0 million capacity. The company reported $240.9 million in cash, cash equivalents and marketable securities as of year-end 2025. The proxy also discloses regulatory setbacks: the FDA placed the RGX-121 program on clinical hold in January 2026 and issued a Complete Response Letter in February 2026; the company is developing responses to both actions.
REGENXBIO Inc: The Vanguard Group filed Amendment No. 10 to its Schedule 13G/A stating it beneficially owns 0 shares of Common Stock (CUSIP 75901B107) and holds 0% of the class. The filing says an internal realignment on January 12, 2026 caused disaggregated reporting by subsidiaries that previously reported with Vanguard.
REGENXBIO Inc. entered into a Settlement and Release Agreement with GlaxoSmithKline LLC to resolve a dispute related to their 2009 license sublicensing arrangement. Under the agreement, REGENXBIO will pay $10.0 million to GSK within three business days of the agreement’s effective date for alleged underpayment of sublicense fees on amounts received from sublicensees, including royalties. The parties are granting each other mutual releases for all past claims connected to the sublicense and certain specified future claims, while REGENXBIO will continue paying GSK under existing sublicense agreements using its current allocation methodology.
REGENXBIO Inc. Chief Medical Officer Steve Pakola reported an open-market sale of 5,124 shares of common stock at $10.35 per share. After this transaction, he directly holds 247,926 shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance as part of routine portfolio management.
REGENXBIO Inc. is a clinical-stage gene therapy company built on its proprietary NAV AAV platform, used in internal programs and by licensees such as Novartis’ Zolgensma and Itvisma. The company focuses its own pipeline on retinal, neuromuscular and neurodegenerative diseases.
Key assets include sura-vec (ABBV-RGX-314) for wet AMD and diabetic retinopathy, partnered with AbbVie, with two pivotal wet AMD trials fully enrolled and a Phase IIb/III DR trial (NAAVIGATE) expected to start dosing in 2Q 2026. RGX-202 for Duchenne muscular dystrophy is in the pivotal phase of the AFFINITY DUCHENNE trial, targeting an accelerated approval BLA in 2026.
RGX-121 for MPS II, partnered with Nippon Shinyaku, showed strong CSF biomarker reductions and enabled a BLA filing, but the FDA issued a Complete Response Letter and placed RGX-121 and RGX-111 (for MPS I) on clinical hold after a PLAG1-family CNS tumor case in the RGX-111 study. REGENXBIO emphasizes its in-house 2,000‑liter NAVXpress manufacturing platform and cGMP facility, as well as substantial collaboration and royalty revenues from AbbVie, Nippon Shinyaku and NAV Technology Licensees.
REGENXBIO Inc. reported strong revenue growth but continued losses for the quarter and year ended December 31, 2025. Full-year revenue rose to $170.4 million from $83.3 million, mainly from its Nippon Shinyaku collaboration and higher Zolgensma and Itvisma royalties. Net loss narrowed to $193.9 million, or $3.76 per share, from $227.1 million, or $4.59 per share. Cash, cash equivalents and marketable securities totaled $240.9 million, and the company expects this to fund operations into early 2027.
Late-stage gene therapy programs advanced, led by RGX-202 for Duchenne muscular dystrophy with positive 18‑month functional data and pivotal topline results expected in early Q2 2026. Sura-vec (ABBV‑RGX‑314) for retinal diseases is moving toward pivotal readouts and a potential $100 million AbbVie milestone upon first patient dosing in the NAAVIGATE trial expected in Q2 2026. However, the FDA placed clinical holds on RGX‑111 and RGX‑121 and issued a complete response letter for the RGX‑121 BLA, which the company is working to address.
REGENXBIO Inc. is registering up to $150 million of common stock for an at-the-market offering through Leerink Partners, which will act as sales agent for a fee of up to 3.0% of gross proceeds. Shares may be sold from time to time on Nasdaq under the symbol RGNX or in other permitted transactions.
The company estimates it held about $241 million of cash, cash equivalents and marketable securities as of December 31, 2025 and currently expects this to fund operations into early 2027. Despite this, REGENXBIO states that there is substantial doubt about its ability to continue as a going concern within 12 months of filing its 2025 Form 10‑K and anticipates an auditor opinion including a going‑concern explanatory paragraph.
Regulatory setbacks add to the risk profile. The FDA issued a Complete Response Letter for RGX‑121, outlining several scientific concerns, and placed clinical holds on RGX‑111 and RGX‑121 after a neoplasm was observed in one RGX‑111 trial participant. The company warns these issues, along with potential dilution—illustrated by a scenario where 17,647,058 shares are sold at $8.50 per share—could materially affect its business and stock price.